Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

EHA 2019 /
PET after 2 cycles of ABVD in patients with early-stage favourable Hodgkin lymphoma

13th - 16th Jun 2019

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 20.06.19
Views: 673

Michael Fuchs - University Hospital of Cologne, Cologne, Germany

Michael Fuchs speaks to ecancer at the 2019 European Hematology Association (EHA) Annual Meeting about research looking at PET after 2 cycles of ABVD in patients with early-stage favourable Hodgkin lymphoma treated within the phase III GHSG HD16 study.

He explains that by using PET scans the trial intended to find out if it is possible for patients to not need radiotherapy after the chemotherapy.

He reports that one of the main findings was that if radiotherapy was not applied to PET negative patients then tumour control was lost.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation